Castle Creek Biosciences, Inc., is a late-stage company developing re-dosable gene therapies. It is preparing to launch a pivotal clinical trial of its lead candidate, D-Fi, for patients with dystrophic epidermolysis bullosa (DEB).
To create transformative therapies that improve lives of people living with genetic diseases.
Castle Creek Biosciences is a portfolio company of Paragon Biosciences.
Paragon is a global life science leader that creates, builds and funds innovative biology-based companies. It accelerates scientific breakthroughs to treat and cure diseases.
People affected by dystrophic epidermolysis bullosa (DEB), a genetic disease that has limited treatment options, inspired us to develop an innovative therapy for this devastating condition.
Tailoring our therapeutic approach for the unique needs of each targeted indication
